{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:17:11Z","timestamp":1761895031158},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3411,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Health and Labor Science Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1093\/annonc\/mdq008","type":"journal-article","created":{"date-parts":[[2010,2,20]],"date-time":"2010-02-20T01:30:11Z","timestamp":1266629411000},"page":"1699-1705","source":"Crossref","is-referenced-by-count":16,"title":["Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events"],"prefix":"10.1016","volume":"21","author":[{"given":"H.","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Oki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Taji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Kuwatsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Seto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Kagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Morishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq008_bb0010","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq008_bb0015","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq008_bb0020","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq008_bb0025","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq008_bb0030","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq008_bb0035","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S1083-8791(00)70028-0","article-title":"Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma","volume":"6","author":"Flinn","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1093\/annonc\/mdq008_bb0040","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":"Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)","volume":"102","author":"Gianni","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq008_bb0045","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2003-04-1257","article-title":"Rituximab as adjuvant to high-dose therapy and autologous haematopoietic cell transplantation for aggressive non-Hodgkin lymphoma","volume":"103","author":"Horwitz","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq008_bb0050","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3816\/CLM.2009.n.087","volume":"9","author":"Kato","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1093\/annonc\/mdq008_bb0055","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2141.2005.05827.x","article-title":"Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device","volume":"132","author":"van Heeckeren","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdq008_bb0060","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1056\/NEJM200306263482620","article-title":"Neutropenia in patients treated with rituximab","volume":"348","author":"Voog","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq008_bb0065","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.1365-2141.2003.04385.x","article-title":"Delayed-onset neutropenia associated with rituximab therapy","volume":"121","author":"Chaiwatanatorn","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdq008_bb0070","first-page":"361","article-title":"High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation","volume":"89","author":"Cairoli","year":"2004","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdq008_bb0075","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/sj.bmt.1704467","article-title":"Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma","volume":"33","author":"Lemieux","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdq008_bb0080","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/annonc\/mdl393","article-title":"A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study","volume":"18","author":"Nitta","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq008_bb0085","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/ije\/24.1.183","article-title":"Prognostic models and the propensity score","volume":"24","author":"Drake","year":"1995","journal-title":"Int J Epidemiol"},{"key":"10.1093\/annonc\/mdq008_bb0090","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0145-2126(01)00183-7","article-title":"Evidence for T-large granular lymphocyte-mediated neutropenia in rituximab-treated lymphoma patients: report of two cases","volume":"26","author":"Papadaki","year":"2002","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdq008_bb0095","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq008_bb0100","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1365-2133.2007.08189.x","article-title":"Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases","volume":"157","author":"Rios-Fern\u00e1ndez","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1093\/annonc\/mdq008_bb0105","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/ard.2007.081166","article-title":"Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis","volume":"67","author":"Marotte","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1093\/annonc\/mdq008_bb0110","doi-asserted-by":"crossref","first-page":"20878","DOI":"10.1073\/pnas.0709205105","article-title":"Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice","volume":"104","author":"Bouaziz","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1093\/annonc\/mdq008_bb0115","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2007-02-068999","article-title":"Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura","volume":"110","author":"Stasi","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1093\/annonc\/mdq008_bb0120","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdp484","article-title":"Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma","volume":"21","author":"Kasamon","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq008_bb0125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2007-04-085092","article-title":"PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma","volume":"111","author":"Leseux","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq008_bb0130","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1038\/sj.onc.1210365","article-title":"Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in hemo\/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions","volume":"26","author":"Bonavida","year":"2007","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdq008_bb0135","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2004-08-3198","article-title":"B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis","volume":"106","author":"Dunleavy","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq008_bb0140","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.3324\/haematol.11031","article-title":"Late-onset neutropenia following rituximab results from a haematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery","volume":"92","author":"Terrier","year":"2007","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdq008_bb0145","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00277-008-0455-2","article-title":"Late-onset neutropenia following viral bone marrow depression after rituximab therapy","volume":"87","author":"Christopeit","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdq008_bb0150","first-page":"1245","article-title":"B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application","volume":"35","author":"Mease","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1093\/annonc\/mdq008_bb0155","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1530\/eje.1.02140","article-title":"The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option","volume":"154","author":"El Fassi","year":"2006","journal-title":"Eur J Endocrinol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419394086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419394086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/8\/1699\/360060\/mdq008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:28:06Z","timestamp":1624519686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419394086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0923753419394086"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq008","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}